QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,654
Employees5,654
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,654
Employees5,654

QGEN Key Statistics

Market cap
7.49B
Market cap7.49B
Price-Earnings ratio
18.90
Price-Earnings ratio18.90
Dividend yield
0.72%
Dividend yield0.72%
Average volume
2.04M
Average volume2.04M
High today
$36.60
High today$36.60
Low today
$35.46
Low today$35.46
Open price
$36.12
Open price$36.12
Volume
982.29K
Volume982.29K
52 Week high
$57.82
52 Week high$57.82
52 Week low
$32.53
52 Week low$32.53

Stock Snapshot

The current QIAGEN(QGEN) stock price is $36.33, with a market capitalization of 7.49B. The stock trades at a price-to-earnings (P/E) ratio of 18.90 and offers a dividend yield of 71.9%.

As of 2026-06-01, QIAGEN(QGEN) stock has fluctuated between $35.46 and $36.60. The current price stands at $36.33, placing the stock +2.4% above today's low and -0.8% off the high.

The QIAGEN(QGEN)'s current trading volume is 982.29K, compared to an average daily volume of 2.04M.

In the last year, QIAGEN(QGEN) shares hit a 52-week high of $57.82 and a 52-week low of $32.53.

In the last year, QIAGEN(QGEN) shares hit a 52-week high of $57.82 and a 52-week low of $32.53.

QGEN News

Simply Wall St 1d
Is It Time To Reconsider Qiagen After Recent Share Price Weakness?

Wondering if Qiagen's share price around US$36.59 reflects a fair deal or a mispricing that could matter for your returns? This article walks through what the v...

Is It Time To Reconsider Qiagen After Recent Share Price Weakness?
Simply Wall St 2d
Qiagen’s New Ebola Assays Test Investor Views On Undervalued Shares

Qiagen launched new digital PCR assays for Bundibugyo ebolavirus surveillance, expanding its infectious disease research tools. The assays are research use onl...

Qiagen’s New Ebola Assays Test Investor Views On Undervalued Shares
TipRanks 3d
UBS Discloses 2.45% Stake in Qiagen via AFM Notification

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

57%

of 21 ratings
Buy
42.9%
Hold
57.1%
Sell
0%

More QGEN News

Simply Wall St 6d
Does QuantiFERON Guidance Cut and Shareholder Probe Change The Bull Case For Qiagen?

In May 2026, Qiagen revised its growth guidance for its QuantiFERON tuberculosis testing product, prompting a shareholder rights investigation by Bronstein, Gew...

Does QuantiFERON Guidance Cut and Shareholder Probe Change The Bull Case For Qiagen?

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.